Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari

Importance of early screening and diagnosis of CKD in T2DM

This paper reviews the burden of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) and describes how clinicians can best utilise early screening and diagnosis together with renal protective therapies to improve patient outcomes.

READ MORE

Importance of early screening and diagnosis of CKD in T2DM

This paper reviews the burden of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) and describes how clinicians can best utilise early screening and diagnosis together with renal protective therapies to improve patient outcomes.

READ MORE

Importance of early screening and diagnosis of CKD in T2DM

This paper reviews the burden of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) and describes how clinicians can best utilise early screening and diagnosis together with renal protective therapies to improve patient outcomes.

READ MORE

Latest News

Subtypes of Type 2 Diabetes by Clinical Parameters
publish-date 17/12/2021

# # #

Subtypes of Type 2 Diabetes by Clinical Parameters

Type 2 diabetes (T2DM) is increasingly recognised as a highly heterogeneous disease, with individuals with varying clinical characteristics, disease progression, drug response, and risk of complications

Read More
SURPASS-1: tirzepatide vs. semaglutide
publish-date 13/12/2021

# # #

SURPASS-1: tirzepatide vs. semaglutide

Results from the open-label, randomised SURPASS-2 trial, assessing the novel dual GIP (glucose-dependent insulinotropic polypeptide)/GLP-1 (glucagon-like peptide 1) receptor agonist tirzepatide vs. human GLP-1 receptor agonist semaglutide in 1,878 type 2 diabetes patients inadequately controlled with metformin, conferred statistically significant HbA1c and body weight reductions from baseline compared to semaglutide in all three treatment arms (tirzepatide 5 mg, 10 mg, and 15 mg).

Read More
Empaglifozin effects in patients with heart failure
publish-date 08/12/2021

# # #

Empaglifozin effects in patients with heart failure

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown reduction in hospitalisation for heart failure (HHF) and serious adverse renal events risks, beyond their glucose-lowering benefits. More specifically, patients with type 2 diabetes who received SGLT2 inhibitors in large-scale, randomised, placebo-controlled trials experienced a 30% to 35% lower risk of HHF compared with patients who received placebo, even though most of them did not have a history of heart failure at baseline.

Read More
 Subgroup analysis of CREDENCE trial on the effects of canagliflozin on heart failure and CV death
publish-date 09/12/2021

# # #

Subgroup analysis of CREDENCE trial on the effects of canagliflozin on heart failure and CV death

This paper reviews the burden of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) and describes how clinicians can best utilise early screening and diagnosis together with renal protective therapies to improve patient outcomes.

Read More
Importance of early screening and diagnosis of CKD in T2DM
publish-date 08/12/2021

# # #

Importance of early screening and diagnosis of CKD in T2DM

Mollis pretium lorem primis senectus habitasse lectus scelerisque donec, ultricies tortor suspendisse adipiscing fusce morbi volutpat pellentesque, consectetur mi risus molestie curae malesuada cum. Dignissim lacus convallis massa mauris enim.

Read More